More Blogs... Read Next
About this Blog
by OldeGuy
created May 2020
in News Blogs
581 Views
Last Viewed: Apr 17
Last Commented: May 2020
OldeGuy has 78 other Blogs
OldeGuy Blogs (78)
Feeling Creative?
Report Blogs that break rules, are offensive, or contain fighting. Staff may not be aware of the Blog Abuse, and cannot do anything about it unless you tell us about it. click to Report Blog Abuse »
If one of the comments is offensive, please report the comment instead (there is a link in each comment to report it).
If one of the comments is offensive, please report the comment instead (there is a link in each comment to report it).
Comments (15)
The virus doesn't 'care' about the politics of the person infected. It just seeks more hosts to replicate within. It will eventually likely infect those who do not take appropriate micobiologic precautions. Currently that is the only weapon against it. Ultimately, a broad vaccine that contains several antigens may be necessary to mostly eradicate this pathogen. Initially any effective vaccine against it will be welcomed, but it may not be enough in all regions.
I understand that to be... not 'a' second wave, but 'the' second wave.
Chatillion - unless a vaccine comes along soon, we will likely see a line of infection waves roll across the globe - airplane travel bringing the virus back again and again until the we reach a world wide herd immunity levels.
I worry that CRISPR may cause the virus to be altered so that it may inadvertently become more pernicious...food for thought.
And yes there are dangers involved, which is why testing and more testing is an essential part of the process. In vitro testing in the lab and in vivo tests on various lab animals. And still the process is incomplete as lastly we have to bridge the gap from laboratory scale to mass production and world wide distribution.
"The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the virus, its manufacturer, Moderna, announced on Monday.
The findings are based on results from the first eight people who each received two doses of the experimental vaccine, starting in March.
Those people, healthy volunteers ages 18 to 55, made antibodies that were then tested in infected cells in the lab, and were able to stop the virus from replicating — the key requirement for an effective vaccine. The levels of those so-called neutralizing antibodies matched or exceeded the levels found in patients who had recovered after contracting the virus in the community."